Scientists Find a Potential Cure for Chronic Hepatitis B - The New York Times
GSK's bepirovirsen achieved a functional cure in ~20% of chronic hepatitis B patients in late-stage Phase III trials, a historically unprecedented result for a disease with ~300 million sufferers globally. The data creates a meaningful re-rating catalyst for GSK, with a partnered royalty upside for Ionis Pharmaceuticals, though the consensus is already mixed and the stock barely moved on the news.
What happened
GSK's bepirovirsen achieved a functional cure in ~20% of chronic hepatitis B patients in late-stage Phase III trials, a historically unprecedented result for a disease with ~300 million sufferers globally.
The read · May 28
Long IONS over GSK on bepirovirsen data — Ionis holds royalty rights and is smaller-cap, meaning the same drug has more leverage on the equity than on GSK's diversified book.
Wrong if
FDA/EMA regulatory path is unclear — 'functional cure' in 20% may not satisfy a label claim sufficient to displace entecavir/tenofovir standards of care, which are cheap generics; any signal of a narrow label or subgroup limitations collapses the pair. Also, IONS carries its own pipeline credit risk unrelated to this program.
CoverageSource: Google News · Published here THU, MAY 28 · 4:30 AM ET · the only report in this recordHow this is decided →
The chart · GSKTradingView · third-party feed, not the Wire’s licensed closes
🔒 Click to interact · scroll moves the page
The story1 min read
The read, in fullWhy it matters
Bepirovirsen is a GSK-Ionis partnered antisense oligonucleotide. A 20% functional cure rate is clinically unprecedented for hep B and is likely to drive upward estimate revisions for both companies, but the impact is larger on IONS proportionally given its market cap is roughly 1/10th of GSK's. GSK consensus is a cluttered 5SB/8B/15H/4S — the Hold-heavy mix means incremental buyers have already priced in pipeline optionality. IONS gets disproportionate news flow credit with a cleaner setup if the street upgrades bepirovirsen royalty value. The GSK short leg is a hedge, not a conviction short — GSK is down only 0.7% today, suggesting the market isn't fully awarding the data yet, but size and diversification cap the upside.
The arc● Open · no developments yet
· Published
The read above, as written. kept as written · closes shown from MAY 28 on
Next · what would move this
2-4 weeks, into analyst day / label updates. Follow to be told when one lands.
Since this story · named here, equal weight · 1D EOD-12.8%
MAY 28 · first close after publicationSEP 3
Price context does not establish that the story caused the move.
Receipts
Google News — the original4:30 AM
Research, not advice.
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →